As we observe #ColorectalCancerAwarenessMonth, new research examines how community physicians navigate third-line treatment for metastatic disease.

Read more here: https://bit.ly/40w377q

#CCAM #crcsm #mCRC

🔷 This approval bolsters biomarker-driven strategies in first-line metastatic colorectal cancer, giving clinicians a new evidence-based option to improve patient outcomes.

🔗 Read more: bit.ly/ONCOnews25Fe...

#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #ColorectalCancer #mCRC #Cancer

CAPRI-2 GOIM Exploratory Analysis: HER2 (ERBB2) Alterations Signal Inferior Outcomes With 1L FOLFIRI + Cetuximab in mCRC - OncoDaily CAPRI-2 GOIM Exploratory Analysis: HER2 (ERBB2) Alterations Signal Inferior Outcomes With 1L FOLFIRI + Cetuximab in mCRC / cancer, cancer care, Cancer

CAPRI-2 GOIM Study Findings: Exploring the Impact of HER2 (ERBB2) Alterations in mCRC Treated With 1L FOLFIRI + Cetuximab

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRC #CAPRI-2GOIM

ASCP and Pfizer Partner to Enhance Biomarker Testing for mCRC Treatment: New Grant Opportunities Announced The American Society for Clinical Pathology and Pfizer initiate an RFP for grants aimed at improving biomarker testing in metastatic colorectal cancer, up to $250k each.

ASCP and Pfizer Partner to Enhance Biomarker Testing for mCRC Treatment: New Grant Opportunities Announced #United_States #Chicago #Pfizer #mCRC #ASCP

Poor Neighborhoods Linked to Early-Onset CRC Mortality Investigators assessed the association between race, ethnicity and neighborhood-level SES with mortality among young adults with mCRC.

Living in neighborhoods with lower #socioeconomic status is linked to an increased risk of death among young adults with metastatic #colorectalcancer. Published in @jamaoncology.com.

https://bit.ly/49Srock

#mCRC #crcsm

Atezolizumab Plus mFOLFOX6/Bevacizumab Yields PFS Benefit in First-Line dMMR/MSI-H mCRC | OncLive The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Atezolizumab Plus mFOLFOX6/Bevacizumab Yields PFS Benefit in First-Line dMMR/MSI-H #mCRC @ascocancer.bsky.social #GI25 #oncology

www.onclive.com/view/atezoli...

#ONCOnews #OncoAlert #OncEd #mCRC #Oncology #ASCO #GI26 #CombinationTherapy

🔗 Read more: bit.ly/ONCOnews09J-01

#ONCOnews #OncoAlert #OncEd #ColorectalCancer #mCRC #Oncology #ClinicalTrials

Among young adults with #mCRC, 3-year survival was lower for Black patients and those in the lowest neighborhood-level #SES quintile; after adjustment, only SES remained significantly associated with mortality. ja.ma/4aKl0G2

CAVE-2 GOIM Trial Results: ctDNA-Guided Cetuximab Rechallenge in MSS RAS/BRAF Wild-Type Metastatic Colorectal Cancer - OncoDaily CAVE-2 GOIM Trial Results: ctDNA-Guided Cetuximab Rechallenge in MSS RAS/BRAF Wild-Type Metastatic Colorectal Cancer / Avelumab, cancer, cancer care, Cancer

CAVE-2 GOIM Trial Results: ctDNA-Guided Cetuximab Rechallenge in MSS RAS/BRAF Wild-Type Metastatic Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CAVE-2GOIM #mCRC #ColorectalCancer #MetastaticColorectalCancer

Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC - OncoDaily Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC / AGEO multicenter study, cancer,

Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AGEO #mCRC

Antonio García-Trevijano,"Pasiones de servidumbre". p. 119. Ed. MCRC #García-Trevijano #ServidumbreVoluntaria #MCRC

Antonio García-Trevijano,"La servidumbre voluntaria". p. 54. Ed. MCRC #García-Trevijano #ServidumbreVoluntaria #MCRC

Scientists report that #sintilimab plus #anlotinib demonstrates promising efficacy and manageable safety in treatment-naïve #mCRC, achieving an ORR of 48.3%, DCR of 89.7%, median PFS of 8.6 months, and OS of 22.9 months. #medsky

#FeaturedArticle in #STTT: doi.org/10.1038/s413...

A reminder that stellar Australian researchers at the Murdoch Children's Research Centre pioneered this immune-system research & new recommendations on feeding babies & toddlers to avoid allergies where possible, now being confirmed worldwide. Yay. #MCRC #allergies

First clinical results of XB2001, an IL-1α–targeting #antibody, show promising efficacy and safety in #chemoresistant #mCRC when combined with FTD/TPI and #bevacizumab, demonstrating improved PFS and reduced IL-6 levels. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

🌟 Discover #Avastin ( #Bevacizumab): Targeting Tumor Blood Supply!

❓ How does it block #VEGF and stop tumor growth?
⚡ Key therapy for #mCRC & #NSCLC.
💊 Trusted worldwide for cancer care.

🔗 Learn more: dengyuemed.com/product/avas...

#HongKongDrugWholesaleDistributor
#HongKongDengYueMedicine

First event of Mornington Chasers's winter Series Regent's Park 10k. After yesterday's Royal Park closed due to high winds, this morning it was crisp and clear sunshine with only a light breeze. I was the 70 mins pacer this run helped a few runners to get under that time. #running #10k #mcrc

Colorectal Cancer Briefing | Sagely Health | Substack Your concise scan of the latest breakthroughs & new trials for colorectal cancer. Click to read Colorectal Cancer Briefing, by Sagely Health, a Substack publication. Launched 8 days ago.

...with capecitabine. Early-phase (safety/dose first).

NCT07114601.

Details: colorectalcancer.substack.com/i/173210547/...

#mCRC #Theranostics

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

➡️ buff.ly/XfueJAy

#CTCs #mCRC #Prognosis #Oncology #CRCSM

8 New Colorectal Cancer Clinical Trials (Sept 2025) From ctDNA to KRAS: What’s New in Colorectal Cancer Trials This Month

Learn More (free CRC briefing): colorectalcancer.substack.com/p/8-new-colo...

#mCRC #ClinicalTrials

ASCO Publications

🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟

✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive

#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch

ascopubs.org/doi/10.1200/...

XB2001, combined with FTD/TPI and #bevacizumab, demonstrated a favourable safety profile and promising efficacy in the third-line treatment of #mCRC, underscoring its biological and clinical relevance. #medsky

#STTT #OpenAccess: www.nature.com/articles/s41...

Oncology Weekly News – August 4th 2025 🔬🧬 Oncology Updates: Ivonescimab Approved, Imfinzi Fast Tracked, TEVIMBRA EU Nod and More   From China’s sNDA acceptance for ivonescimab […] The post Oncology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Oncology Weekly News – August 4th 2025 #News #Mesothelioma #HCC #Oncology #mCRC Comment below!

Oncology Weekly News – August 4th 2025 🔬🧬 Oncology Updates: Ivonescimab Approved, Imfinzi Fast Tracked, TEVIMBRA EU Nod and More   From China’s sNDA acceptance for ivonescimab […] The post Oncology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Oncology Weekly News – August 4th 2025 #News #Mesothelioma #HCC #Oncology #mCRC Comment below!

Oncology Weekly News – August 4th 2025 🔬🧬 Oncology Updates: Ivonescimab Approved, Imfinzi Fast Tracked, TEVIMBRA EU Nod and More   From China’s sNDA acceptance for ivonescimab […] The post Oncology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Oncology Weekly News – August 4th 2025 #News #Mesothelioma #HCC #Oncology #mCRC Comment below!

Yan Leyfman: New Hope in Irinotecan-Refractory Metastatic Colorectal Cancer - OncoDaily Yan Leyfman: New Hope in Irinotecan-Refractory Metastatic Colorectal Cancer / cancer, colorectal cancer, mCRC, Metastatic colorectal cancer, OncoDaily,

New Hope in Irinotecan-Refractory Metastatic Colorectal Cancer - Yan Leyfman
@yleyfman.bsky.social

oncodaily.com/science/yan-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRC #ColorectalCancer

Take your #mCRC care to the next level! Join us Aug. 20 📅 at 7:00 pm CT for Precision in Practice, a FREE webinar. Learn how early testing & collaboration can improve mCRC outcomes. Sponsored by an independent educational grant from Pfizer. Sign up here: www.asge.org/home/educati... #GISky #MedSky

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - OncoDaily Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial / Agenus, botensilimab, Cancer research,

Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Botensilimab #Balstilimab #CRC #mCRC #CororectalCancer

CheckMate 8HW Trial in MSI-H/dMMR mCRC: ESMO GI 2025 The CheckMate 8HW trial presented at ESMO GI 2025 showed improvements in health-related quality of life for patients with MSI-H/dMMR mCRC

ESMO GI 2025 Highlights: CheckMate 8HW Trial on HRQoL in MSI-H/dMMR mCRC with NIVO + IPI
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #CheckMate8HW #mCRC #ColorectalCancer